Purpuric drug eruption with leukocytoclastic vasculitis due to gefitinib

Hiroshi UCHIMIYA

Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan

Search for more papers by this author

Yuko HIGASHI,

Yuko HIGASHI

Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan

Search for more papers by this author

Kazuhiro KAWAI,

Kazuhiro KAWAI

Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan

Search for more papers by this author

Takuro KANEKURA,

Takuro KANEKURA

Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan

Search for more papers by this author

Hiroshi UCHIMIYA,

Hiroshi UCHIMIYA

Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan

Search for more papers by this author

Yuko HIGASHI,

Yuko HIGASHI

Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan

Search for more papers by this author

Kazuhiro KAWAI,

Kazuhiro KAWAI

Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan

Search for more papers by this author

Takuro KANEKURA,

Takuro KANEKURA

Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan

Search for more papers by this author

First published: 24 May 2010

https://doi.org/10.1111/j.1346-8138.2010.00896.x

Citations: 12

Hiroshi Uchimiya, M.D., Ph.D., Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan. Email: [email protected]

Share a link

Email
Wechat
Bluesky

References

1 Baselga J. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol 2000; 18: 54–59.
CAS PubMed Web of Science® Google Scholar
2 Nanney LB, Magrid M, Stoscheck CM, Carpenter G, King LE. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 1984; 83: 385–393.
10.1111/1523-1747.ep12264708
CAS PubMed Web of Science® Google Scholar
3 Kurokawa I, Endo K, Hirabayashi M. Purpuric drug eruption possibly due to gefitinib (Iressa®). Int J Dermatol 2005; 44: 167–168.
10.1111/j.1365-4632.2005.02185.x
CAS PubMed Web of Science® Google Scholar
4 Fernández-Guarino M, Marquet Ryan A, Pérez-García B, Gónzalez-López C, Jaén Olasolo P. Necrotizing vasculitis due to gefitinib (Iressa®). Int J Dermatol 2007; 46: 890–891.
10.1111/j.1365-4632.2007.03275.x
PubMed Web of Science® Google Scholar
5 Sheen YS, Hsiao CH, Chu CY. Severe purpuric xerotic dermatitis associated with gefitinib therapy. Arch Dermatol 2008; 144: 269–270.
10.1001/archdermatol.2007.53
PubMed Web of Science® Google Scholar
6 Lee MW, Seo CW, Kim SW et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004; 84: 23–26.
10.1080/00015550310005898
CAS PubMed Web of Science® Google Scholar
7 Uchihara M, Ejima T, Uchihira T, Araki J, Kamei T. Cutaneous side effects in 19 lung cancer patients treated with gefitinib. Nishi-Nihon Hihu 2004; 66: 602–607 (in Japanese).
10.2336/nishinihonhifu.66.602
Google Scholar

Citing Literature

Volume37, Issue6

June 2010

Pages 562-564

Purpuric drug eruption with leukocytoclastic vasculitis due to gefitinib

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Purpuric drug eruption with leukocytoclastic vasculitis due to gefitinib

References

Citing Literature

References

Related

Information